Monoclonal Antibodies (mAbs) Global Market Opportunities and Strategies to 2033

This report describes and explains the monoclonal antibodies (mAbs) market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global monoclonal antibodies (mAbs) market reached a value of nearly $209.85 billion in 2023, having grown at a compound annual growth rate (CAGR) of 12.8% since 2018. The market is expected to grow from $209.85 billion in 2023 to $ 375.41 billion in 2028 at a rate of 12.3%. The market is then expected to grow at a CAGR of 12.4% from 2028 and reach $673.13 billion in 2033.

Growth in the historic period resulted from the strong economic growth in emerging markets, increasing focus on personalized medicine, increase in R&D expenditure and government initiatives. Factors that negatively affected growth in the historic period were pricing pressures from regulators.

Going forward, increasing chronic diseases, rise in healthcare expenditure, increasing prevalence of cancer and increasing aging population will drive the growth. Factor that could hinder the growth of the monoclonal antibodies (mAbs) market in the future include high cost in development of monoclonal antibodies, stringent regulatory guidelines and usage of surrogate endpoints in clinical trials.

The monoclonal antibodies (mAbs) market is segmented by source into murine, chimeric, humanized and human. The human market was the largest segment of the monoclonal antibodies (mAbs) market segmented by source, accounting for 43.2% or $90.59 billion of the total in 2023. Going forward, the humanized segment is expected to be the fastest growing segment in the monoclonal antibodies (mAbs) market segmented by source, at a CAGR of 14.2% during 2023-2028.

The monoclonal antibodies (mAbs) market is segmented by application into anti-cancer, immunological, infectious diseases, hematological disease and other applications. The anti-cancer market was the largest segment of the monoclonal antibodies (mAbs) market segmented by application, accounting for 38.9% or $81.66 billion of the total in 2023. Going forward, the immunological segment is expected to be the fastest growing segment in the monoclonal antibodies (mAbs) market segmented by application, at a CAGR of 13.4% during 2023-2028.

The monoclonal antibodies (mAbs) market is segmented by end-users into hospitals, specialty centers and other end-users. The hospitals market was the largest segment of the relays market segmented by end-users, accounting for 65.4% or $137.33 billion of the total in 2023. Going forward, the specialty centers segment is expected to be the fastest growing segment in the relays market segmented by end-users, at a CAGR of 13% during 2023-2028.

North America was the largest region in the monoclonal antibodies (mAbs) market, accounting for 45.8% or $96.11 billion of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the monoclonal antibodies (mAbs) market will be Asia Pacific and Western Europe where growth will be at CAGRs of 13.6% and 12.9% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 12.5% and 9.20% respectively.

The global monoclonal antibodies (mAbs) market is concentrated, with a few large players operating in the market. The top ten competitors in the market made up 41.8% of the total market in 2022. Johnson & Johnson Inc. was the largest competitor with a 13.3% share of the market, followed by Merck & Co., Inc. with 11.2%, F. Hoffman-La Roche Ltd. with 5.4%, Bristol Myers Squibb with 4.4%, GlaxoSmithKline plc with 3.4%, Eli Lilly And Company with 1.3%, Pfizer Inc with 1.2%, Amgen Inc., with 1.1%, Novartis AG with 0.5% and Eisai Co., Ltd with 0.2%.

The top opportunities in the monoclonal antibodies (mAbs) market segmented by source will arise in the human segment, which will gain $80.22 billion of global annual sales by 2028. The top opportunities in the monoclonal antibodies (mAbs) market segmented by application will arise in the anti-cancer segment, which will gain $65.85 billion of global annual sales by 2028. The top opportunities in the monoclonal antibodies (mAbs) market segmented by end-users will arise in the hospitals segment, which will gain $108.45 billion of global annual sales by 2028. The monoclonal antibodies (mAbs) market size will gain the most in USA at $67.88 billion.

Market-trend-based strategies for the monoclonal antibodies (mAbs) market include investment in targeted and combination therapy, strategic partnerships and collaborations among market players to drive innovation and expansion in the market, R&D investments revolutionizing treatment, integration of artificial intelligence for accelerated innovation, product innovation in novel therapies and biosimilars. Expands Treatment Options.

Player-adopted strategies in the monoclonal antibodies (mAbs) market include focus on expanding its operations by new product launches, business capabilities through strategic partnerships and enhancing its geographic presence through strategic partnerships.

To take advantage of the opportunities, the analyst recommends the monoclonal antibodies (mAbs) companies to focus on advancing targeted and combination therapies for market growth, focus on driving market growth through product innovation, focus on cancer biologics R&D, focus on revolutionizing research with AI integration, focus on human and humanized segments for growth, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations, focus on diversifying distribution channels, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on strategic promotion, focus on immunological and anti-cancer segments and focus on specialty centers and hospitals for strategic growth.